BLRX (BioLine Rx) FFO


BLRX BioLine Rx Ltd BLRX
23 GF Score
Price $3.09
! 5 Warning Signs
View Full Analysis

What is BioLine Rx FFO?

FFO (Funds from operations) only applies to REITs.

BLRX
23GF Score
BioLine Rx Ltd BLRX
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioLine Rx Business Description

Other Exchanges BLRX:IsraelYP2:Germany
Address 2 HaMa’ayan Street, Modi’in, ISR, 7177871
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
23GF Score

Get the complete analysis for BLRX

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.09
Price